Schedule Killed Pfizer IP Suit, AntiCancer Tells Fed. Circ.

By Jonathan Randles (April 11, 2013, 6:48 PM EDT) -- California biotech firm AntiCancer Inc. on Tuesday asked the Federal Circuit to revive its suit accusing Pfizer Inc. and Crown BioScience Inc. of infringing cancer imaging patents, saying local patent rules and an unreasonable schedule stopped it from presenting its case properly....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as